latest news releases from the newsroom
Radius Health Announces That it Has Hired Dr. Lorraine Fitzpatrick, Former GlaxoSmithKline Development Leader for Denosumab, as Chief Medical Officer
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline, responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
Reis, Inc. to Announce Second Quarter 2015 Results on Thursday, July 30, 2015
NEW YORK, July 27, 2015 (GLOBE NEWSWIRE) -- Reis, Inc. (Nasdaq:REIS) ("Reis" or the "Company"), a leading provider of commercial real estate market information and analytical tools, announced that it will release its second quarter 2015 results on the morning of Thursday, July 30, 2015. The complete release will also be available directly at either of the following web pages:
Independent Bank Group, Inc.
Independent Bank Group Reports Second Quarter Financial Results
MCKINNEY, Texas, July 27, 2015 (GLOBE NEWSWIRE) -- Independent Bank Group, Inc. (NASDAQ:IBTX), the holding company for Independent Bank, today announced net income available to common shareholders of $10.5 million, or $0.61 per diluted share, for the quarter ended June 30, 2015 compared to $5.1 million, or $0.32 per diluted share, for the quarter ended June 30, 2014 and $9.4 million, or $0.55 per diluted share, for the quarter ended March 31, 2015.